Published in Blood Weekly, April 14th, 2005
Issues such as the number of people that could be harboring vCJD as carriers, the impact on the blood supply and new risk reduction measures were addressed. Pall Corporation (PLL) presented an overview of the latest research on its prion reduction technology as a new risk reduction measure to help prevent transfusion transmission of infectious prions that can cause vCJD. The company expects to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.